Business
TME Pharma Appoints Diede van den Ouden as New CEO at the 2025 Annual General Meeting of Shareholders
BERLIN, June 25, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the unanimous approval of all resolutions submitted to its 2025 annual general meeting of shareholders (AGM), including the appointment of Diede van den Ouden as sole member of the board of directors and Chief Executive Officer as a successor to Ar
About this update from Tme Pharma N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":313,"url":"https://media.zenfs.com/en/business-wire.com/adb0f4705d7ba42e650f44ad894aa7ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TsOIMohSAc5m5jPMQJYg9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/adb0f4705d7ba42e650f44ad894aa7ff","width":960,"height":300},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Iz0Lz7mKG0TbmY2UPgTwmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD02MjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/adb0f4705d7ba42e650f44ad894aa7ff","width":1000,"height":313}},"lazy":false},{"type":"text","content":"BERLIN, June 25, 2025--(BUSINESS WIRE)--Regulatory News:","length":56,"tagName":"p"},{"type":"text","content":"TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the unanimous approval of all resolutions submitted to its 2025 annual general meeting of shareholders (AGM), including the appointment of Diede van den Ouden as sole member of the board of directors and Chief Executive Officer as a successor to Aram Mangasarian. The shareholders representing 16.67% of the total issued and outstanding share capital on May 28, 2025, were represented at the AGM which took place on June 25, 2025, at 03:00 p.m. CEST.","length":662,"tagName":"p"},{"type":"text","content":""On behalf of the Board and the entire TME Pharma team I would like to welcome Diede van den Ouden as our new CEO. Diede’s commitment to TME Pharma, demonstrated both as a significant shareholder and an active supporter, gives us great confidence as we enter this next chapter," said Maurizio PetitBon, Chairman of TME Pharma. "I would also like to extend our heartfelt thanks to Aram for his invaluable leadership over the past years during which TME Pharma achieved tremendous advances, especially with regard to the industry-leading clinical data generated in glioblastoma – one of the most challenging areas in oncology. We wish Aram the very best in his next venture and are pleased that he will stay involved with the TME R&D programs on an advisory basis. The Supervisory...